Influence of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) on Glycolytic Metabolism of Canine Glioma: A Potential Improvement in Cancer Metabolism
The transcription factor hypoxia-inducible factor 1α (HIF-1α) drives metabolic reprogramming in gliomas (GLs) under hypoxic conditions, promoting glycolysis for tumor development. Evofosfamide (EVO) releases a DNA-alkylating agent within hypoxic regions, indicating that it may serve as a hypoxia-tar...
Main Authors: | Hiroki Yamazaki, Seio Onoyama, Shunichi Gotani, Tatsuya Deguchi, Masahiro Tamura, Hiroshi Ohta, Hidetomo Iwano, Hidetaka Nishida, Peter J. Dickinson, Hideo Akiyoshi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-11-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/23/5537 |
Similar Items
-
Evofosfamide Is Effective against Pediatric Aggressive Glioma Cell Lines in Hypoxic Conditions and Potentiates the Effect of Cytotoxic Chemotherapy and Ionizing Radiations
by: Quentin Bailleul, et al.
Published: (2021-04-01) -
Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models
by: Julia K. Harms, et al.
Published: (2019-07-01) -
Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years
by: Anas Najjar, et al.
Published: (2020-02-01) -
AI-Radiomics Can Improve Inclusion Criteria and Clinical Trial Performance
by: Michal R. Tomaszewski, et al.
Published: (2022-02-01) -
Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy
by: Zhe Fu, et al.
Published: (2021-04-01)